170 related articles for article (PubMed ID: 38534951)
21. Ductal Spread Versus High-Grade Prostatic Intraepithelial Neoplasia: A Diagnostic Pitfall.
Acosta AM; Sharif A; Groth JV; Kajdacsy-Balla A
Int J Surg Pathol; 2016 Dec; 24(8):718-719. PubMed ID: 27605089
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical verification of ductal differentiation in prostate cancer.
Tarján M; Lenngren A; Hellberg D; Tot T
APMIS; 2012 Jun; 120(6):510-8. PubMed ID: 22583364
[TBL] [Abstract][Full Text] [Related]
23. [Clinical characteristics of prostatic adenocarcinoma with ductal features].
Yamashita R; Matsuzaki M; Matsui T; Yamaguchi R; Yuen K; Niwakawa M; Tobisu K
Nihon Hinyokika Gakkai Zasshi; 2008 Mar; 99(3):525-30. PubMed ID: 18404881
[TBL] [Abstract][Full Text] [Related]
24. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
25. A Japanese patient with ductal carcinoma of the prostate carrying an adenomatosis polyposis coli gene mutation: a case report.
Umeda K; Kosaka T; Nakamura K; Takeda T; Mikami S; Nishihara H; Oya M
Diagn Pathol; 2020 Aug; 15(1):102. PubMed ID: 32758244
[TBL] [Abstract][Full Text] [Related]
26. Prostate-Specific Membrane Antigen Uptake Heterogeneity in Mixed Ductal-Acinar Adenocarcinoma of the Prostate.
Zhao Q; Dong A; Bai Y; Zuo C
Clin Nucl Med; 2023 Aug; 48(8):750-752. PubMed ID: 37290403
[TBL] [Abstract][Full Text] [Related]
27. Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.
Rao SR; Protheroe A; Cerundolo L; Maldonado-Perez D; Browning L; Lamb AD; Bryant RJ; Mills IG; Woodcock DJ; Hamdy FC; Tomlinson IPM; Verrill C
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628903
[TBL] [Abstract][Full Text] [Related]
28. Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma.
Iakymenko OA; Lugo I; Kwon D; Zhao W; Hayee A; Punnen S; Parekh DJ; Pollack A; Ritch CR; Gonzalgo ML; Stoyanova R; Jorda M; Kryvenko ON
Urology; 2020 Mar; 137():108-114. PubMed ID: 31711982
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate.
Lindh C; Kis L; Delahunt B; Samaratunga H; Yaxley J; Wiklund NP; Clements M; Egevad L
APMIS; 2019 Aug; 127(8):554-560. PubMed ID: 31127651
[TBL] [Abstract][Full Text] [Related]
30. Variants of acinar adenocarcinoma of the prostate mimicking benign conditions.
Humphrey PA
Mod Pathol; 2018 Jan; 31(S1):S64-70. PubMed ID: 29297496
[TBL] [Abstract][Full Text] [Related]
31. Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study.
Wu YP; Chen SH; Wang ST; Li XD; Cai H; Lin YZ; Xue XY; Wei Y; Zheng QS; Xu N
Oncotarget; 2017 Apr; 8(17):29048-29055. PubMed ID: 28423709
[TBL] [Abstract][Full Text] [Related]
32. PIN-like (Ductal) Adenocarcinoma of the Prostate.
Paulk A; Giannico G; Epstein JI
Am J Surg Pathol; 2018 Dec; 42(12):1693-1700. PubMed ID: 30138215
[TBL] [Abstract][Full Text] [Related]
33. Genetic profile of ductal adenocarcinoma of the prostate.
Seipel AH; Whitington T; Delahunt B; Samaratunga H; Mayrhofer M; Wiklund P; Grönberg H; Lindberg J; Egevad L
Hum Pathol; 2017 Nov; 69():1-7. PubMed ID: 28457729
[TBL] [Abstract][Full Text] [Related]
34. Histological variants of prostatic carcinoma and their significance.
Humphrey PA
Histopathology; 2012 Jan; 60(1):59-74. PubMed ID: 22212078
[TBL] [Abstract][Full Text] [Related]
35. [Clinical Characteristics of Prostate Ductal Adenocarcinoma in Kyoto University Hospital].
Nakamura K; Terada N; Kobayashi T; Sugino Y; Yamasaki T; Matsui Y; Imamura M; Okubo K; Kamba T; Yoshimura K; Ogawa O
Hinyokika Kiyo; 2015 Dec; 61(12):487-91. PubMed ID: 26790762
[TBL] [Abstract][Full Text] [Related]
36. [Differential expression of LLGL2 in prostate ductal adenocarcinoma and acinar adenocarcinoma and its significance].
Zhang W; Wang M; Liu LT; Cui D; Liu M; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2023 Oct; 52(10):1012-1016. PubMed ID: 37805392
[No Abstract] [Full Text] [Related]
37. Current Understanding and Management of Intraductal Carcinoma of the Prostate.
Considine B; Adeniran A; Hurwitz ME
Curr Oncol Rep; 2021 Jul; 23(9):110. PubMed ID: 34272624
[TBL] [Abstract][Full Text] [Related]
38. Genomic analysis of aggressive ductal adenocarcinoma of the prostate.
Kobayashi H; Kosaka T; Nakamura K; Kimura T; Nishihara H; Oya M
Cancer Med; 2023 Apr; 12(7):8445-8451. PubMed ID: 36573306
[TBL] [Abstract][Full Text] [Related]
39. Ductal carcinoma of the prostate shows a different immunophenotype from high grade acinar cancer.
Jardel P; Debiais C; Godet J; Irani J; Fromont G
Histopathology; 2013 Jul; 63(1):57-63. PubMed ID: 23701402
[TBL] [Abstract][Full Text] [Related]
40. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
